ACLS vs LRCX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
LRCX is the larger of the two ($229.44B market cap): the incumbent the market prices for continued execution (14.97x forward earnings, beta 2.01). ACLS is the smaller challenger ($2.80B), priced similarly on forward earnings (14.63x): more room to run, but more to prove. If the story you believe is ACLS's (Memory recovery (DRAM and HBM)), ACLS is the more direct way to own it; if it is LRCX's (AI-driven chip-capex supercycle), LRCX is.
ACLS vs LRCX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ACLS | LRCX | What it tells you |
|---|---|---|---|
| Market cap | $2.80B | $229.44B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 14.63 | 14.97 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 27.00 | 27.37 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.89 | 2.01 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 14% of range | 16% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.52 | 16.50 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ACLS and LRCX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACLS and LRCX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACLS and LRCX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Axcelis Technologies (ACLS) do?
Axcelis Technologies designs and sells ion implantation equipment for the semiconductor industry, along with the aftermarket service and spare parts (its CS&I business) that keep those tools running. Ion implantation is the process step that shoots charged atoms into silicon wafers to change their electrical properties, and it is essential to making almost every chip. The company's Purion product family serves a wide range of end markets, including power devices (notably silicon carbide chips used in electric vehicles and industrial systems), image sensors, general mature-node logic, and memory such as DRAM and high-bandwidth memory (HBM). Ion implantation makes up the large majority of revenue, so Axcelis is a fairly pure play on that one process step rather than a diversified equipment giant.
What does Lam Research (LRCX) do?
Lam Research is one of the largest semiconductor equipment makers in the world, specializing in wafer-fabrication tools used to build integrated circuits. It is a leader in two critical process steps: etch (precisely removing material to carve nanoscale features) and deposition (laying down ultra-thin films of material), along with related cleaning and surface-preparation systems. These steps are repeated hundreds of times to build modern 3D chip structures, and Lam's tools are essential to manufacturing advanced logic and especially memory chips (DRAM and NAND flash). Lam sells its systems to the world's leading chipmakers and foundries, then earns a large, recurring stream of revenue from spare parts, upgrades, and services for its big installed base of tools, which smooths the cyclical equipment-sales business. Demand is driven by capital spending from semiconductor manufacturers, which rises and falls with chip-industry cycles but trends structurally higher as AI, data centers, and advanced devices require more and more sophisticated chips. Headquartered in Fremont, California, Lam is a key enabler of leading-edge and memory chip production.
ACLS vs LRCX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ACLS drivers: Memory recovery (DRAM and HBM); Power devices and silicon carbide.
- LRCX drivers: AI-driven chip-capex supercycle; Leadership in etch and deposition.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Axcelis is a small, highly cyclical company whose results swing with semiconductor capital-spending cycles it does not control, and its concentration in ion implantation means a slump in that step or in key end markets (like silicon carbide power chips) hits it hard, as the 2024 to 2025 revenue decline showed. For LRCX, semiconductor equipment is highly cyclical, and Lam's new-tool sales swing sharply with chipmaker capital-spending cycles, especially in memory, which is among the most volatile end markets.
ACLS or LRCX: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate ACLS from LRCX. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACLS and LRCX guides.
ACLS vs LRCX: the full fundamentals
ACLS. At ~$90.49 on November 20, 2026, Axcelis trades at about 27x trailing earnings, which are depressed, and ~15x forward estimates that assume EPS rises from ~$4.54 in 2026 to ~$6.20 in 2027. The stock fell ~28% over three months as gross margins slipped and the Veeco close was pushed out, even though revenue grew and bookings jumped. A net cash balance of roughly $400 million cushions the cycle. All figures are approximate and change with each quarter and the market.
LRCX. At about $184 on November 20, 2026, Lam trades near 27 times trailing earnings and about 15 times analysts' fiscal 2028 EPS estimate of ~$12.27, a sharp compression from roughly 47x trailing in October even though earnings kept rising. The 30 analysts covering it have a mean target of about $362, nearly double the price, which shows how far the market's read on AI-driven memory and logic capex has moved away from the published estimates (fiscal 2027 revenue near $35.4 billion). The next report, estimated for late January 2027, carries consensus EPS of about $2.35 on ~$8.64 billion of revenue.
Headline figures (approximate, November 2026): ACLS shows revenue (ttm) ~$890 million (Q3 2026 up ~11.3% yoy), revenue (fy2025) ~$839 million, net income (ttm) ~$105 million (~12% margin), q3 2026 revenue ~$238 million (EPS ~$1.26 vs ~$1.11 est.); LRCX shows revenue (ttm) ~$26.1 billion (September 2026 quarter ~$8.22B, +54% y/y), margins Gross ~51%, operating ~37%, net ~32% (Q1 FY2027 non-GAAP gross 52.4%), net income (ttm) ~$8.45 billion (EPS ~$6.71), p/e (trailing / forward) ~27x / ~15x.
The bottom line: ACLS vs LRCX
ACLS and LRCX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ACLS and LRCX exposure against your real portfolio. It is not an investment adviser.
Wondering how ACLS or LRCX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Axcelis Technologies
Ask Walnut's AI anything about ACLS and see how it fits what you own.
FAQ
What is the difference between ACLS and LRCX?
+
Axcelis Technologies designs and sells ion implantation equipment for the semiconductor industry, along with the aftermarket service and spare parts (its CS&I business) that keep those tools running. Lam Research is one of the largest semiconductor equipment makers in the world, specializing in wafer-fabrication tools used to build integrated circuits. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ACLS or LRCX the better stock?
+
Neither is universally better. LRCX is the larger incumbent; ACLS is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ACLS or LRCX?
+
On forward P/E (as of November 2026), ACLS trades at 14.63x and LRCX at 14.97x, so ACLS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ACLS and LRCX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ACLS vs LRCX?
+
ACLS: Axcelis is a small, highly cyclical company whose results swing with semiconductor capital-spending cycles it does not control, and its concentration in ion implantation means a slump in that step or in key end markets (like silicon carbide power chips) hits it hard, as the 2024 to 2025 revenue decline showed. A large share of demand comes from China (about 46% of third-quarter 2026 revenue), exposing the company to export controls, tariffs, and geopolitical tension that could restrict sales. The pending Veeco merger adds execution risk: its close has slipped to an expected end of the first quarter of 2027 while it awaits clearance in China, faces integration challenges, and could dilute or distract even if it closes. Margins are a fresh concern: second-quarter 2026 non-GAAP gross margin fell to ~42.7% from ~45.2% and non-GAAP operating margin to ~14.7% from ~17.7%, and third-quarter gross margin of ~41.2% missed the ~43% outlook, mainly on currency moves in the Korean won, so a beat on revenue and EPS still sent the shares lower. Customer concentration, competition from much larger equipment makers, and the general volatility of a roughly $2.8 billion market-cap chip-equipment stock, which swung between ~$73.60 and ~$193.78 over the past year and fell ~28% in the three months to November 20, 2026, round out the risks. LRCX: Semiconductor equipment is highly cyclical, and Lam's new-tool sales swing sharply with chipmaker capital-spending cycles, especially in memory, which is among the most volatile end markets. US export restrictions on advanced chipmaking equipment to China are a significant headwind, since China has been a large customer; tighter rules can cut a meaningful slice of revenue. Customer concentration among a handful of large chipmakers, intense competition from Applied Materials and Tokyo Electron, and sensitivity to memory pricing and macro demand all add risk. A downturn in chip capex or escalating trade restrictions would pressure results and the stock. China rose to 35% of revenue in the September 2026 quarter, so any tightening lands on a larger base, and management already expects that share to fall significantly in the December quarter. Valuation has been the other risk: at about 47 times trailing earnings in October the shares priced in a strong fiscal 2027, and the ~42% drop over the three months to November 20, 2026, during a quarter of record revenue, shows how quickly sentiment on AI capex can turn.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ACLS or LRCX; figures are approximate and dated (as of November 2026). Verify current data before investing.